Gain Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
BETHESDA, Md., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that the Company’s management team will participate in a fireside chat and one-on-one meetings at the Oppenheimer 36
Fireside Chat Details
Date: Wednesday, February 25, 2026
Time: 1:20 p.m. ET
Registered attendees can request one-on-one meetings with Gain management via their Oppenheimer banking representative.
About Gain Therapeutics, Inc.
Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain’s lead drug candidate, GT-02287 is currently being evaluated for the treatment of Parkinson’s disease with or without a GBA1 mutation in a Phase 1b clinical trial. GT-02287 has further potential in Gaucher’s disease, dementia with Lewy bodies, and Alzheimer’s disease. Gain has multiple undisclosed preclinical assets targeting lysosomal storage disorders, metabolic diseases, and solid tumors.
Gain’s unique approach enables the discovery of novel, allosteric small molecule modulators that can restore or disrupt protein function. Deploying its highly advanced Magellan™ platform, Gain is accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders including neurodegenerative diseases, rare genetic disorders and oncology.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Grayscale’s Pandl: Ethereum’s ETH Issuance Model Resembles a Small Country’s Economy
One October 2025 Crypto Black Friday Catalyst is Back: Is Bitcoin in Danger?
Solana Company Posts $30.3M Net Loss in Q2 as Staking Revenue Grows
Lifeway Foods 10% owner Edward Smolyansky sells common shares worth $3.38 million
